Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recently, a
mitochondrial ceramidase
has been identified and cloned, whose mitochondrial localization strongly suggests the existence of an unexpected mitochondrial pathway of ceramide metabolism that may play a key role in mitochondrial functions, especially in the regulation of apoptosis. To explore the biological effect of
mitochondrial ceramidase
on cells, pcDNA 3.1/His-CDase plasmid, containing
mitochondrial ceramidase
cDNA sequence, was transducted into K562 cells mediated by liposome, and G418 was used to screen for positive colonies. A stable transfected K562 cell line was established and named as 'K562TC'. The difference between K562 and K562TC cells in chemotheraputic cytotoxicity response and serum-withdrawal resistance and
Bcl-2
protein expression were evaluated by MTT assay, annexin V/PI test, flow cytometry or Western blotting, respectively. The results showed that although survival was comparable between K562 and K562TC cells after exposed to adriamycin, etoposide or arsenious acid, K562TC cells with elevated
Bcl-2
protein expression level as identified by FCM or Western blotting revealed stronger resistance to apoptosis induced by serum withdrawal than their parental cells. Inhibition of
mitochondrial ceramidase
expression in K562TC cells by its specific antisense oligodeoxynucleotide was correlated with a decrease in
Bcl-2
protein level. N, N-dimethylsphingosine, a sphingosine kinase inhibitor, depleted intracellular sphingosine-1-phosphate production, also abrogated
Bcl-2
protein expression in K562TC cells, while
Bcl-2
protein level in K562 cells was up-regulated by exogenous sphingosine-1-phosphate. It is concluded that
mitochondrial ceramidase
overexpression in K562 cells leads to markedly elevated level of
Bcl-2
protein and results in more resistance to serum withdrawal. This effect is initiated not by sphingosine, the direct metabolite of
mitochondrial ceramidase
, but via sphingosine-1-phosphate, its phosphorylated form. This is the first evidence that
mitochondrial ceramidase
, through its sphingoid metabolite sphingosine-1-phosphate, up-regulates
Bcl-2
protein expression in K562 cells.
...
PMID:mitochondrial ceramidase overexpression up-regulates Bcl-2 protein level in K562 cells, probably through its metabolite sphingosine-1-phosphate. 1549 14